Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Shionogi Aims to Begin Clinical Studies for COVID-19 Vaccine in 2020
Shionogi said on April 27 that it has officially made the decision to develop a prophylactic vaccine against COVID-19 infection. The company is currently in discussions with Japanese regulatory authorities and its research collaborator, the National Institute of Infectious Diseases…
To read the full story
Related Article
- Shionogi Chief Eyes Conditional Approval for COVID-19 Vaccine, Supply by Year’s End If OK’ed
May 11, 2021
- Shionogi Kicks Off Japan PI/PII Study of COVID-19 Vaccine Candidate
December 17, 2020
- Shionogi Preparing Commercial Production of COVID-19 Vaccine Simultaneously with Development
June 22, 2020
- Govt Officials Urge Japan Pharma Companies to Be More Proactive in Coronavirus Vaccine Development
May 12, 2020
- Shionogi Aiming at Clinical Trials of COVID-19 Treatment Candidates in FY2020
April 15, 2020
BUSINESS
- G1 Reform Will Accelerate LLP Transfers, Fuel Competition: LTL Chief
April 15, 2026
- Daiichi Sankyo’s I-DXd Filed in US for SCLC, Wins Priority Review
April 15, 2026
- Nxera’s Partner Earns Taiwan Approval for Daridorexant
April 15, 2026
- Sanofi Japan Sales Rise 4.5% in 2025 as Dupixent Widens Label
April 15, 2026
- Eylea Biosimilar Supply Curbed amid Originator Disruption
April 14, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…